Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
24
08
2018
accepted:
29
08
2018
pubmed:
12
12
2018
medline:
2
7
2020
entrez:
12
12
2018
Statut:
ppublish
Résumé
Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Ocular GVHD has at least three biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have found several novel pathogenic mechanisms, including renin angiotensin system and endoplasmic reticulum stress signaling that can be targeted by therapeutic agents. Many studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. Efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD for optimal care.
Identifiants
pubmed: 30531954
doi: 10.1038/s41409-018-0340-0
pii: 10.1038/s41409-018-0340-0
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
662-673Subventions
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U10 HL069294
Pays : United States
Références
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.
doi: 10.1053/bbmt.2003.50026
pubmed: 12720215
Tichelli A, Duell T, Weiss M, Socie G, Ljungman P, Cohen A, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant. 1996;17:1105–11.
pubmed: 8807122
Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83:1125–30.
pubmed: 10502571
pmcid: 1722843
doi: 10.1136/bjo.83.10.1125
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100:415–9.
pubmed: 12091330
doi: 10.1182/blood-2002-01-0011
Westeneng AC, Hettinga Y, Lokhorst H, Verdonck L, van Dorp S, Rothova A. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea. 2010;29:758–63.
pubmed: 20489577
doi: 10.1097/ICO.0b013e3181ca321c
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–96.
pubmed: 16545722
doi: 10.1016/j.bbmt.2006.02.003
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21:389–401.
doi: 10.1016/j.bbmt.2014.12.001
pubmed: 25529383
Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea. 2012;31:299–310.
pubmed: 22157574
doi: 10.1097/ICO.0b013e318226bf97
Shikari H, Amparo F, Saboo U, Dana R. Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation. Cornea. 2015;34:243–7.
pubmed: 25603230
pmcid: 4318713
doi: 10.1097/ICO.0000000000000340
Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47:1470–3.
pubmed: 22484321
doi: 10.1038/bmt.2012.56
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.
pubmed: 28736335
doi: 10.1016/j.jtos.2017.05.008
Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34.
pubmed: 27713092
doi: 10.1016/j.bbmt.2016.09.023
Ogawa Y, Kuwana M, Yamazaki K, Mashima Y, Yamada M, Mori T, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2003;44:1888–96.
pubmed: 12714620
doi: 10.1167/iovs.02-0699
Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci. 2001;42:111–9.
pubmed: 11133855
Kusne Y, Temkit M, Khera N, Patel DR, Shen JF. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease. Ocul Surf. 2017;15:784–8.
pubmed: 28789979
doi: 10.1016/j.jtos.2017.08.002
Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol. 1989;107:1343–8.
pubmed: 2675805
doi: 10.1001/archopht.1989.01070020413046
Herretes S, Ross DB, Duffort S, Barreras H, Yaohong T, Saeed AM, et al. Recruitment of donor T Cells to the eyes during ocular GVHD in recipients of MHC-matched allogeneic hematopoietic stem cell transplants. Invest Ophthalmol Vis Sci. 2015;56:2348–57.
pubmed: 25655798
pmcid: 4406104
doi: 10.1167/iovs.14-15630
Sakimoto T, Ohnishi T, Ishimori A. Significance of ectodomain shedding of TNF receptor 1 in ocular surface. Invest Ophthalmol Vis Sci. 2014;55:2419–23.
pubmed: 24627147
doi: 10.1167/iovs.13-13265
Schargus M, Meyer-ter-Vehn T, Menrath J, Grigoleit GU, Geerling G. Correlation between tear film osmolarity and the disease score of the international chronic ocular graft-versus-host-disease consensus group in hematopoietic stem cell transplantation patients. Cornea. 2015;34:911–6.
pubmed: 26075459
doi: 10.1097/ICO.0000000000000494
Na KS, Yoo YS, Hwang KY, Mok JW, Joo CK. Tear osmolarity and ocular surface parameters as diagnostic markers of ocular graft-versus-host disease. Am J Ophthalmol. 2015;160:143–9 e141.
pubmed: 25870935
doi: 10.1016/j.ajo.2015.04.002
Jung JW, Han SJ, Song MK, Kim TI, Kim EK, Min YH, et al. Tear cytokines as biomarkers for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:2079–85.
pubmed: 26303101
doi: 10.1016/j.bbmt.2015.08.020
Sapna Tibrewal, Joy Sarkar, Sarmad H. Jassim, Sonal Gandhi, Snehal Sonawane, Shweta Chaudhary, Yong-Soo Byun, Yair Ivanir, Joelle Hallak, John H. Horner, Martin Newcomb, Sandeep Jain, (2013) Tear Fluid Extracellular DNA: Diagnostic and Therapeutic Implications in Dry Eye Disease. Investigative Opthalmology & Visual Science 54:8051
doi: 10.1167/iovs.13-12844
He J, Ogawa Y, Mukai S, Saijo-Ban Y, Kamoi M, Uchino M, et al. In vivo confocal microscopy evaluation of ocular surface with graft-versus-host disease-related dry eye disease. Sci Rep. 2017;7:10720.
pubmed: 28878217
pmcid: 5587759
doi: 10.1038/s41598-017-10237-w
Perez RL, Perez-Simon JA, Caballero-Velazquez T, Flores T, Carrancio S, Herrero C, et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:270–3.
pubmed: 20800691
doi: 10.1016/j.bbmt.2010.08.008
Ogawa Y, Morikawa S, Okano H, Mabuchi Y, Suzuki S, Yaguchi T, et al. MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. eLife. 2016;5:e09394.
pubmed: 26809474
pmcid: 4739756
doi: 10.7554/eLife.09394
Yamane M, Ogawa Y, Mukai S, Yaguchi S, Kamijuku H, Inaba T, et al. Functional role of lacrimal gland fibroblasts in a mouse model of chronic graft-versus-host disease. Cornea. 2018;37:102–8.
pubmed: 29053559
doi: 10.1097/ICO.0000000000001411
Yaguchi S, Ogawa Y, Shimmura S, Kawakita T, Hatou S, Satofuka S, et al. Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. PLoS ONE. 2013;8:e64724.
pubmed: 23762250
pmcid: 3675140
doi: 10.1371/journal.pone.0064724
Mukai S, Ogawa Y, Urano F, Kudo-Saito C, Kawakami Y, Tsubota K. Novel treatment of chronic graft-versus-host disease in mice using the er stress reducer 4-phenylbutyric acid. Sci Rep. 2017;7:41939.
pubmed: 28165054
pmcid: 5292729
doi: 10.1038/srep41939
Ogawa Y, He H, Mukai S, Imada T, Nakamura S, Su CW, et al. Heavy chain-hyaluronan/pentraxin 3 from amniotic membrane suppresses inflammation and scarring in murine lacrimal gland and conjunctiva of chronic graft-versus-host disease. Sci Rep. 2017;7:42195.
pubmed: 28165063
pmcid: 5292704
doi: 10.1038/srep42195
Na KS, Yoo YS, Mok JW, Lee JW, Joo CK. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:1459–64.
pubmed: 26301966
doi: 10.1038/bmt.2015.187
Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242–9.
pubmed: 21791424
pmcid: 3204740
doi: 10.1182/blood-2011-03-344390
Uchino M, Ogawa Y, Uchino Y, Mori T, Okamoto S, Tsubota K. Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. Br J Ophthalmol. 2012;96:34–37.
pubmed: 22053104
doi: 10.1136/bjophthalmol-2011-300514
Kamoi M, Ogawa Y, Uchino M, Tatematsu Y, Mori T, Okamoto S, et al. Donor-recipient gender difference affects severity of dry. Eye Hematop stem Cell Transplant Eye. 2011;25:860–5.
Wang JC, Teichman JC, Mustafa M, O’Donnell H, Broady R, Yeung SN. Risk factors for the development of ocular graft-versus-host disease (GVHD) Dry Eye syndrome in patients with chronic GVHD. Br J Ophthalmol. 2015;99:1514–8.
pubmed: 25947556
doi: 10.1136/bjophthalmol-2014-306438
Pathak M, Diep PP, Lai X, Brinch L, Ruud E, Drolsum L. Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transplant. 2018;53:863–72.
pubmed: 29382955
pmcid: 6039390
doi: 10.1038/s41409-018-0090-z
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–74.
pubmed: 28736342
doi: 10.1016/j.jtos.2017.05.001
Curtis LM, Datiles MB 3rd, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW, et al. Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica. 2015;100:1228–36.
pubmed: 26088932
pmcid: 4800684
doi: 10.3324/haematol.2015.124131
Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004;23:272–85.
pubmed: 15084861
doi: 10.1097/00003226-200404000-00010
Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012;119:487–93.
pubmed: 22153706
doi: 10.1016/j.ophtha.2011.08.040
Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128:94–101.
pubmed: 20065224
doi: 10.1001/archophthalmol.2009.356
Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. 2013;32:1204–10.
pubmed: 23846405
doi: 10.1097/ICO.0b013e318294b0c0
Shimazaki J, Seika D, Saga M, Fukagawa K, Sakata M, Iwasaki M, et al. A prospective, randomized trial of two mucin secretogogues for the treatment of Dry Eye syndrome in office workers. Sci Rep. 2017;7:15210.
pubmed: 29123104
pmcid: 5680274
doi: 10.1038/s41598-017-13121-9
Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65–76.
pubmed: 27725302
doi: 10.1016/j.jtos.2016.09.003
Arita R, Minoura I, Morishige N, Shirakawa R, Fukuoka S, Asai K, et al. Development of definitive and reliable grading scales for meibomian gland dysfunction. Am J Ophthalmol. 2016;169:125–37.
pubmed: 27345733
doi: 10.1016/j.ajo.2016.06.025
Murube J. Characteristics and etiology of conjunctivochalasis: historical perspective. Ocul Surf. 2005;3:7–14.
pubmed: 17131001
doi: 10.1016/S1542-0124(12)70118-0
Schirra F, Hoh H, Kienecker C, Ruprecht KW. Using LIPCOF (lid-parallel conjunctival fold) for assessing the degree of dry eye, it is essential to observe the exact position of that specific fold. Adv Exp Med Biol. 1998;438:853–8.
pubmed: 9634978
doi: 10.1007/978-1-4615-5359-5_120
Nemeth J, Fodor E, Lang Z, Kosina-Hagyo K, Berta A, Komar T, et al. Lid-parallel conjunctival folds (LIPCOF) and dry eye: a multicentre study. Br J Ophthalmol. 2012;96:1380–5.
pubmed: 22952403
doi: 10.1136/bjophthalmol-2012-301580
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984–99.
pubmed: 25796139
pmcid: 4744804
doi: 10.1016/j.bbmt.2015.02.025
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:348–71.
pubmed: 22178693
doi: 10.1016/j.bbmt.2011.12.519
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15.
pubmed: 25398933
pmcid: 4304105
doi: 10.1182/blood-2014-08-551994
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.
doi: 10.1016/S1470-2045(09)70225-6
pubmed: 19695955
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–30.
pubmed: 20124511
pmcid: 2858487
doi: 10.1182/blood-2009-11-251595
Ogawa Y, Kim SK, Dana R, Clayton J, Jain S, Rosenblatt MI, et al. International chronic ocular graft-vs-host-disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013;3:3419.
pubmed: 24305504
pmcid: 3851919
doi: 10.1038/srep03419
Rapoport Y, Freeman T, Koyama T, Engelhardt BG, Jagasia M, Savani BN, et al. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric. Cornea. 2017;36:258–63.
pubmed: 28060078
doi: 10.1097/ICO.0000000000001109
Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16:1611–28.
pubmed: 20601036
doi: 10.1016/j.bbmt.2010.06.015
Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21:1167–87.
pubmed: 25838185
pmcid: 4821166
doi: 10.1016/j.bbmt.2015.03.024
Inamoto Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, et al. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18:1517–24.
pubmed: 22683612
pmcid: 3443259
doi: 10.1016/j.bbmt.2012.05.016
Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92:3098–104.
pubmed: 9787144
doi: 10.1182/blood.V92.9.3098
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187–93.
pubmed: 15852025
doi: 10.1038/sj.bmt.1704984
Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667–74.
doi: 10.1182/blood-2008-03-141481
pubmed: 18621929
Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion. 2010;50:1359–69.
pubmed: 20113452
doi: 10.1111/j.1537-2995.2009.02577.x
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–62.
pubmed: 16551963
pmcid: 1895490
doi: 10.1182/blood-2006-01-0233
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935–42.
pubmed: 20663943
pmcid: 2966917
doi: 10.3324/haematol.2010.026104
Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409–17.
pubmed: 16042691
doi: 10.1111/j.1365-2141.2005.05616.x
Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:47–55.
pubmed: 15625544
doi: 10.1016/j.bbmt.2004.10.004
Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25:1067–71.
pubmed: 10828867
doi: 10.1038/sj.bmt.1702410
Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003;88:837–9.
pubmed: 12857569
Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol. 2006;83:80–85.
pubmed: 16443558
doi: 10.1532/IJH97.05111
Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol. 1995;79:1007–11.
pubmed: 8534643
pmcid: 505317
doi: 10.1136/bjo.79.11.1007
Yamane M, Ogawa Y, Fukui M, Kamoi M, Uchino M, Saijo-Ban Y, et al. Long-term topical diquafosol tetrasodium treatment of dry eye disease caused by chronic graft-versus-host disease: a retrospective study. Eye Contact Lens. 2018;44 suppl 2:S215-20.
doi: 10.1097/ICL.0000000000000455
Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017;124:43–52.
pubmed: 27817918
doi: 10.1016/j.ophtha.2016.09.023
Dry Eye A, Management Study Research G, Asbell PA, Maguire MG, Pistilli M, Ying GS. et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378:1681–90.
doi: 10.1056/NEJMoa1709691
Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115–20.
pubmed: 15177961
doi: 10.1016/j.ophtha.2003.10.019
Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003;31:579–83.
pubmed: 12692625
doi: 10.1038/sj.bmt.1703862
Leite SC, de Castro RS, Alves M, Cunha DA, Correa ME, da Silveira LA, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2006;38:223–7.
pubmed: 16785864
doi: 10.1038/sj.bmt.1705426
Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25:1101–3.
pubmed: 10828873
doi: 10.1038/sj.bmt.1702334
Zallio F, Mazzucco L, Monaco F, Astori MR, Passera R, Drago G, et al. A single-center pilot prospective study of topical application of platelet-derived eye drops for patients with ocular chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1664–70.
pubmed: 27269196
doi: 10.1016/j.bbmt.2016.05.023
Sabti S, Halter JP, Braun Frankl BC, Goldblum D. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant. 2012;47:981–4.
pubmed: 22041848
doi: 10.1038/bmt.2011.205
Geerling G, Tost FH. Surgical occlusion of the lacrimal drainage system. Dev Ophthalmol. 2008;41:213–29.
pubmed: 18453771
doi: 10.1159/000131091
Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea. 2007;26:1195–9.
pubmed: 18043175
doi: 10.1097/ICO.0b013e318155743d
Takahide K, Parker PM, Wu M, Hwang WY, Carpenter PA, Moravec C, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1016–21.
pubmed: 17697963
pmcid: 2168033
doi: 10.1016/j.bbmt.2007.05.006
Inamoto Y, Sun YC, Flowers ME, Carpenter PA, Martin PJ, Li P, et al. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:2002–7.
pubmed: 26189353
pmcid: 4604037
doi: 10.1016/j.bbmt.2015.07.013
Magro L, Gauthier J, Richet M, Robin M, Nguyen S, Suarez F, et al. Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. Bone Marrow Transplant. 2017;52:878–82.
pubmed: 28218751
doi: 10.1038/bmt.2017.9
Korb DR, Blackie CA. Using goggles to increase periocular humidity and reduce dry eye symptoms. Eye Contact Lens. 2013;39:273–6.
pubmed: 23771008
doi: 10.1097/ICL.0b013e3182960ff9
Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.
pubmed: 12695712
doi: 10.1097/01.ICL.0000060998.20142.8D
Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171–5.
pubmed: 16371776
doi: 10.1097/01.ico.0000176611.88579.0a
Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92.
pubmed: 8328549
doi: 10.1016/S0002-9394(14)71750-7
Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–9.
pubmed: 10768324
doi: 10.1016/S0161-6420(99)00176-1
Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008;41:293–302.
pubmed: 17982500
doi: 10.1038/sj.bmt.1705900
Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33:1031–5.
pubmed: 15048138
doi: 10.1038/sj.bmt.1704453
Abud TB, Amparo F, Saboo US, Di Zazzo A, Dohlman TH, Ciolino JB, et al. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Ophthalmology. 2016;123:1449–57.
pubmed: 27086024
doi: 10.1016/j.ophtha.2016.02.044
Jung JW, Lee YJ, Yoon SC, Kim TI, Kim EK, Seo KY. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2015;159:519–27 e511.
pubmed: 25498356
doi: 10.1016/j.ajo.2014.11.035
Kheirkhah A, Di Zazzo A, Satitpitakul V, Fernandez M, Magilavy D, Dana R. A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of janus kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease. Cornea. 2017;36:799–804.
pubmed: 28445193
doi: 10.1097/ICO.0000000000001206
Ogawa Y, Dogru M, Uchino M, Tatematsu Y, Kamoi M, Yamamoto Y, et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant. 2010;45:565–9.
pubmed: 19633693
doi: 10.1038/bmt.2009.173
Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131:715–23.
pubmed: 23599118
pmcid: 4167802
doi: 10.1001/jamaophthalmol.2013.195
Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, et al. Lifitegrast for the treatment of dry eye disease: results of a phase iii, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124:53–60.
pubmed: 28079022
doi: 10.1016/j.ophtha.2016.09.025
Peris-Martinez C, Menezo JL, Diaz-Llopis M, Avino-Martinez JA, Navea-Tejerina A, Risueno-Reguillo P. Multilayer amniotic membrane transplantation in severe ocular graft-versus host disease. Eur J Ophthalmol. 2001;11:183–6.
pubmed: 11456023
doi: 10.1177/112067210101100215
Yeh PT, Hou YC, Lin WC, Wang IJ, Hu FR. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. J Formos Med Assoc. 2006;105:334–9.
pubmed: 16618614
doi: 10.1016/S0929-6646(09)60139-X
Meller D, Fuchsluger T, Pauklin M, Steuhl KP. Ocular surface reconstruction in graft-versus-host disease with HLA-identical living-related allogeneic cultivated limbal epithelium after hematopoietic stem cell transplantation from the same donor. Cornea. 2009;28:233–6.
pubmed: 19158575
doi: 10.1097/ICO.0b013e31818526a6
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076